Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Valeo Pharma Inc VPHIF

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


GREY:VPHIF - Post by User

Comment by Royal10on Apr 14, 2021 2:45pm
149 Views
Post# 32994113

RE:Valeo Pharma To Raise $4.0 Million Via 9-Month Debentures

RE:Valeo Pharma To Raise $4.0 Million Via 9-Month DebenturesCould we see a more bullish buy signal? Insiders are buying a NON-BROKERED private placement of debentures yielding 8% just after having announced that  the company will begin to
sell two new products in major provinces of Canada.
The stock was also recommended by  IA Capital Markets analyst Chelsea Stellick that raised her share target for Valeo Pharma ($1.14) to $3.10 from $2.20, while maintaining her "buy" recommendation, on April 6th|2021.
Insiders control more than half of the issued shares. 
<< Previous
Bullboard Posts
Next >>